Haleon increased U.S. sales by marketing products to consumers experiencing side effects from GLP-1 weight-loss drugs. The company partnered with CVS to create dedicated in-store sections for brands like TUMS and Advil. These products alleviate common side effects such as nausea and abdominal pain associated with medications like Wegovy.
This strategic placement resulted in a 24% average sales increase per store where the GLP-1 destination sets were implemented. Haleon currently occupies the majority of this dedicated shelf space at CVS. The initiative targets an emerging consumer segment to drive long-term growth.